Table 3 Measures of intestinal permeability, absorptive capacity, bacterial translocation, and tumour necrosis factor receptor p55, analysed both by treatment allocation and by HIV status
Measure | By treatment allocation | By HIV status* | ||||
|---|---|---|---|---|---|---|
| Â | MM | Placebo | P | HIV positive | HIV negative | P |
| Â | (n = 37) | (n = 49) | Â | (n = 17) | (n = 57) | Â |
Xylose (%) | 21.4 (18.9-27.4) | 21.2 (16.3-26.4) | 0.49 | 20.3 (17.9-23.7) | 21.2 (15.4-27.4) | 0.94 |
R:G | 0.35 (0.32-0.40) | 0.38 (0.34-0.42) | 0.23 | 0.39 (0.35-0.43) | 0.36 (0.32-0.41) | 0.12 |
L:R | 0.057 (0.045-0.088) | 0.048 (0.036-0.071) | 0.12 | 0.059 (0.036-0.071) | 0.050 (0.036-0.077) | 0.49 |
LPS (pg/ml) | 50.7 (24.8-115.1) | 51.6 (22.0-107.9) | 0.52 | 64.7 (29-113) | 51.6 (20-109) | 0.56 |
anti-LPS IgM (units) | 95 (58-148) | 127 (100-175) | 0.047 | 117 (89-134) | 118 (66-190) | 0.46 |
anti-LPS IgG (units) | 115 (63-201) | 152 (64-272) | 0.60 | 142 (98-293) | 153 (63-223) | 0.33 |
TNFp55 (pg/ml) | 1.13 (1.01-1.40) | 1.22 (1.02-1.40) | 0.62 | 1.32 (0.99-1.64) | 1.14 (1.04-1.38) | 0.37 |